Compare RC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | TLSI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 270.2M |
| IPO Year | 2011 | 2020 |
| Metric | RC | TLSI |
|---|---|---|
| Price | $1.36 | $4.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.81 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.0M | 231.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 45.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | $67.36 | $37.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $1.37 | $2.20 |
| 52 Week High | $4.18 | $7.95 |
| Indicator | RC | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 27.77 | 35.40 |
| Support Level | N/A | $4.28 |
| Resistance Level | $1.88 | $4.47 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 1.25 | 2.32 |
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.